The PARAMOUNT trial of valsartan–sacubitril therapy in HFpEF demonstrated a significant relationship between plasma NT-proBNP and decreases in LV systolic longitudinal and circumferential strain, independently of age, sex, systolic and diastolic blood pressure, body mass index, left ventricular ejection fraction, left atrial volume index, atrial fibrillation, and renal function [21,22]. Here, NPPB is linked to atrial fibrillation.